Aktienanalyse zu InMed Pharmaceuticals Inc (INM)INMInMed Pharmaceuticals Inc

InMed Pharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses. The Company's pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer's disease, dry Age-Related Macular Degeneration, or dry AMD, and Epidermolysis Bullosa, or EB. Its INM-901 is a small molecule, disease-modifying drug developed for treatment for Alzheimer's disease. It also offers various modes of administration, including oral delivery. Its INM-089 is a drug candidate for dry age-related macular degeneration. Its INM-755 is a cannabinol cream topical product candidate intended as a therapy in dermatological diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

InMed Pharmaceuticals, now Mentari Therapeutics, is a good buy right now due to its recent merger which is expected to enhance market competitiveness. The stock has shown a 9.20% increase yesterday, indicating positive momentum, and the forward P/E is currently at 0, suggesting potential for future earnings growth. However, the company reported a net income loss of -5,839,392 USD in Q4 2026, which remains a risk factor.